In conclusion, the multi-drug combination regimen using PPARγ ligands could have a key role in the treatment of many malignant tumors, including breast cancer [203], ovarian cancer [204,205], colon cancer [206,207], and lung cancer [208,209]. Here, PPARG is linked to breast carcinoma.